Toxicology specialist Calvert Labs is joining forces with the formulation experts at Particle Sciences to offer an early-stage service package designed to speed up drug development.
India's government is taking seriously the call to better regulate clinical trials, and now the country is planning to launch two independent committees tasked with overseeing the process.
A U.K. court has convicted a former Aptuit employee of manipulating data from hundreds of safety studies, making investigational drugs seem successful when they weren't.
Earlier this month, Radiant Research exited the CRO business, as parent company Clinical Research Advantage shipped out its drug development arm. Now the company is focusing on its remaining core business: maintaining and expanding a network of clinical trial sites.
Two private equity firms are pooling their CRO resources, agreeing to merge the formerly public BioClinica with imaging and cardiac safety contractor CoreLab.
Catalent Pharma Solutions is betting big on the Chinese market, launching two joint ventures for its Softgel Technologies and Clinical Supply Solutions businesses.
As many as 2,868 people have died in Indian clinical trials over the past 7 years, and sponsors and CROs have paid out compensation in just 45 of those instances, according to India's Business Standard.
Maryland's Accelovance is stepping up its clinical research capabilities, buying Radiant Development, the CRO arm of Radiant Research.
After clearing about $500 million in revenue last year, Chinese CRO giant WuXi PharmaTec is expecting between 13% and 15% growth in 2013, counting on an increase in big-name partnerships and an expansion of the local drug market.
Canadian CDMO Patheon more than doubled its losses last quarter, but the company says that's just a hiccup as it integrates the newly acquired Banner Pharmacaps and pushes toward its goal of $1 billion in annual revenue.
PRA has snatched up CRO ClinStar, giving it a foothold in the growing Eastern European outsourcing market.
According to CenterWatch's latest Global Investigative Site Relationship survey, clinical trial sites voted Biogen Idec, Forest Laboratories and Bayer the best sponsors, giving them the best marks on 36 relationship attributes.
Covance is stepping up its personalized medicine services, teaming up with the biomarker-focused M2Gen to better identify ideal patients for oncology drug trials.
As the science behind innovative treatments gets more and more sophisticated, poor solubility has become a serious concern for drug developers. With that in mind, Chinese CRO Crystal Pharmatech has partnered with drug delivery-focused contractor Particle Sciences to offer formulation solutions to clients.
Fresh off spending $72 million on IT outfit Liquent, Parexel says it's hardly finished expanding through M&A, keeping its eye on small technology companies and contractors in the Middle East for future deals.
Capsugel is doubling down on its formulation and manufacturing business, buying Scotland's Encap Drug Delivery to expand its services.
Synteract has closed a deal to acquire Germany's Harrison Clinical Research, rebranding itself as SynteractHCR and expanding its reach to 16 countries.
French CRO CiToxLAB posted 25% revenue growth in 2012, excellent results that shine compared to the overall results for the preclinical research market.
ShangPharma is putting its plans to go private in front of shareholders on March 20, asking for approval on a deal that would sell the company to a group of private equity outfits for $173 million.
Last week's big news that Quintiles is finally going public left one burning question: How much will the company raise in its IPO?